Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Buffered SalineDrug: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- AIM Therapeutics Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01501942
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦Institut de cardiologie et de pneumologie de l'Hôpital Laval, Laval, Quebec, Canada
News
No news found